Identification and characterization of small-molecule inhibitors of hepsin

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2008-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-08-0446PMID 18852137PMCID PMC2659609
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers

  2021cited by this paper
• Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery

  2008cited by this paper
• Pro-urokinase-type Plasminogen Activator Is a Substrate for Hepsin*

  2006cited by this paper
• Molecular markers of prostate cancer.

  2006cited by this paper
• Protease inhibitors and their peptidomimetic derivatives as potential drugs

  2006cited by this paper
• Hepsin activates pro‐hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor‐1B (HAI‐1B) and HAI‐2

  2005cited by this paper
• Protease inhibitors in the clinic.

  2005cited by this paper
• Hepsin Paradox Reveals Unexpected Complexity of Metastatic Process

  2004cited by this paper
• Hepsin promotes prostate cancer progression and metastasis.

  2004cited by this paper
• Probucol Inactivates ABCA1 in the Plasma Membrane with Respect to Its Mediation of Apolipoprotein Binding and High Density Lipoprotein Assembly and to Its Proteolytic Degradation*

  2004cited by this paper
• The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain.

  2003cited by this paper
• Protein Binding in Antiretroviral Therapies

  2003cited by this paper
• Effects of AGI-1067 and Probucol After Percutaneous Coronary Interventions

  2003cited by this paper
• HEPSIN inhibits cell growth/invasion in prostate cancer cells.

  2002cited by this paper
• Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance.

  2002cited by this paper
• Expression profiling reveals hepsin overexpression in prostate cancer.

  2001cited by this paper
• Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.

  2001cited by this paper
• Delineation of prognostic biomarkers in prostate cancer

  2001cited by this paper
• The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.

  2000cited by this paper
• Suppression of the Invasive Capacity of Human Breast Cancer Cells by Inhibition of Urokinase Plasminogen Activator via Amiloride and B428

  2000cited by this paper
• Imaging proteolysis by living human breast cancer cells.

  2000cited by this paper
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

  1999cited by this paper
• Expression of the Factor VII Activating Protease, Hepsin, in situ in Renal Cell Carcinoma

  1998cited by this paper
• The crystal structure of human α‐thrombin complexed with LY178550, a nonpeptidyl, active site‐directed inhibitor

  1997cited by this paper
• Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.

  1997cited by this paper
• Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes.

  1996cited by this paper
• MDL 29311, an analog of probucol, decreases triglycerides in rats by increasing hepatic clearance of very-low-density lipoprotein.

  1994cited by this paper
• Human U937 cell surface peptidase activities: characterization and degradative effect on tumor necrosis factor‐α

  1992cited by this paper
• Characterization of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology

  1992cited by this paper
• Murine thymocytes possess specific cell surface‐associated exoaminopeptidase activities: Preferential expression by immature CD4−CD8− subpopulation

  1990cited by this paper
• Comparison of gas chromatography and high-performance liquid chromatography for the analysis of probucol in plasma.

  1986cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer

  2022cites this paper
• Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.

  2020cites this paper
• Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of patent literature

  2020cites this paper
• Cancer Diagnostics of Protease Activity and Metastasis

  2018cites this paper
• Screening Combinatorial Peptide Libraries in Protease Inhibitor Drug Discovery

  2018cites this paper
• Inhibitors of the Growth‐Factor Activating Proteases Matriptase, Hepsin and HGFA: Strategies for Rational Drug Design and Optimization

  2018cites this paper
• Recent Advances of Hepsin-Targeted Inhibitors.

  2017cites this paper
• Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion

  2016cites this paper
• Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.

  2015cites this paper
• Development of a Specific Cell-based Platform to Analyze Proteolytic Activity of Cancer Relevant Serine Proteases

  2015cites this paper
• Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.

  2015cites this paper
• Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

  2014cites this paper
• The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

  2014cites this paper
• Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis

  2014cites this paper
• Title : The Androgen-Regulated Protease TMPRSS 2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis

  2014cites this paper
• Containing Cancer : Hepsin Inhibitors May Block

  2014cites this paper
• An allosteric anti-hepsin antibody derived from a constrained phage display library.

  2012cites this paper
• Effect of Anthralin on Cell Viability in Human Prostate Adenocarcinoma

  2012cites this paper
• Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity

  2012cites this paper
• AWARD NUMBER: W81XWH-10-1-0189 TITLE: Heterobivalent Imaging Agents for Simultaneous Targeting Prostate-Specific Membrane Antigen (PSMA) and Hepsin PRINCIPAL INVESTIGATOR:

  2012cites this paper
• Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen.

  2011cites this paper
• Faulty epithelial polarity genes and cancer.

  2011cites this paper
• Heterobivalent Imaging Agents for Simultaneous Targeting Prostate-Specific Membrane Antigen (PSMA) and Hepsin

  2011cites this paper
• Molecular and Physiological Mechanisms of Membrane Receptor Systems Functioning

  2011cites this paper
• Blockade of LTB4-induced chemotaxis by bioactive molecules interfering with the BLT2-Galphai interaction.

  2010cites this paper
• Isolation, purification, and study of properties of recombinant hepsin from Escherichia coli

  2010cites this paper
• Type II transmembrane serine proteases in cancer and viral infections.

  2009cites this paper